HROW Stock Overview
An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Harrow, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.00 |
| 52 Week High | US$22.63 |
| 52 Week Low | US$7.60 |
| Beta | 0.88 |
| 11 Month Change | 21.95% |
| 3 Month Change | 82.61% |
| 1 Year Change | 13.39% |
| 33 Year Change | 102.51% |
| 5 Year Change | 141.38% |
| Change since IPO | 142.81% |
Recent News & Updates
Recent updates
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
May 02Harrow's Drug Iheezo Is Off To A Great Start
Feb 19Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Jan 30Harrow sells non‑ophthalmic compounding business, terms undisclosed
Oct 05Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye
Sep 27SRK Capital - Harrow Health: Market Missing The Forest For The Trees
Aug 19These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively
Aug 11
Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch
May 23Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
May 12Is Harrow Health (NASDAQ:HROW) A Risky Investment?
Dec 15Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
Aug 24Harrow Health prices 8.625% senior notes due 2026
Jun 15Harrow Health: An 8.3% Baby Bond Yield With Low Balance Sheet Leverage
May 28Shareholders Shouldn’t Be Too Comfortable With Harrow Health's (NASDAQ:HROW) Strong Earnings
May 18Shareholder Returns
| HROW | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 16.9% | 1.0% | 0.5% |
| 1Y | 13.4% | 17.7% | 23.9% |
Return vs Industry: HROW underperformed the US Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: HROW underperformed the US Market which returned 22.9% over the past year.
Price Volatility
| HROW volatility | |
|---|---|
| HROW Average Weekly Movement | 12.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: HROW's share price has been volatile over the past 3 months.
Volatility Over Time: HROW's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 315 | Mark Baum | www.harrow.com |
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.
Harrow, Inc. Fundamentals Summary
| HROW fundamental statistics | |
|---|---|
| Market cap | US$705.16m |
| Earnings (TTM) | -US$31.33m |
| Revenue (TTM) | US$138.68m |
5.4x
P/S Ratio-23.7x
P/E RatioIs HROW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HROW income statement (TTM) | |
|---|---|
| Revenue | US$138.68m |
| Cost of Revenue | US$41.92m |
| Gross Profit | US$96.76m |
| Other Expenses | US$128.09m |
| Earnings | -US$31.33m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 69.77% |
| Net Profit Margin | -22.59% |
| Debt/Equity Ratio | 305.9% |
How did HROW perform over the long term?
See historical performance and comparison